• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALT

    Altimmune Inc.

    Subscribe to $ALT
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.

    IPO Year:

    Exchange: NASDAQ

    Website: altimmune.com

    Recent Analyst Ratings for Altimmune Inc.

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    12/1/2022$20.00Buy
    Goldman
    12/29/2021$30.00Buy
    Jefferies
    6/30/2021$41.00 → $21.00Buy
    B. Riley Securities
    6/30/2021$53.00 → $31.00Market Outperform
    JMP Securities
    See more ratings

    Altimmune Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      11/14/24 11:58:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/17/24 11:16:51 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/16/24 4:21:16 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      7/10/24 6:35:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Altimmune Inc. (Amendment)

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      4/10/24 9:40:25 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Altimmune Inc.

      SC 13G - Altimmune, Inc. (0001326190) (Subject)

      3/5/24 4:30:11 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Altimmune Inc. (Amendment)

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      2/14/24 4:00:26 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Altimmune Inc. (Amendment)

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      2/14/24 12:04:25 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Altimmune Inc. (Amendment)

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      2/14/24 12:02:53 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Altimmune Inc. (Amendment)

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      2/14/24 11:36:18 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Altimmune Inc. SEC Filings

    See more
    • SEC Form EFFECT filed by Altimmune Inc.

      EFFECT - Altimmune, Inc. (0001326190) (Filer)

      3/14/25 12:15:11 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Inc. filed SEC Form 8-K: Other Events

      8-K - Altimmune, Inc. (0001326190) (Filer)

      3/13/25 4:03:28 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Altimmune Inc.

      S-3 - Altimmune, Inc. (0001326190) (Filer)

      2/27/25 4:49:48 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Altimmune Inc.

      S-8 - Altimmune, Inc. (0001326190) (Filer)

      2/27/25 4:36:16 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Altimmune Inc.

      10-K - Altimmune, Inc. (0001326190) (Filer)

      2/27/25 4:30:06 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - Altimmune, Inc. (0001326190) (Filer)

      2/27/25 7:05:35 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Altimmune, Inc. (0001326190) (Filer)

      2/25/25 7:32:20 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

      SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)

      2/14/25 2:31:56 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Inc. filed SEC Form 8-K: Other Events

      8-K - Altimmune, Inc. (0001326190) (Filer)

      12/11/24 5:19:34 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Altimmune Inc.

      10-Q - Altimmune, Inc. (0001326190) (Filer)

      11/12/24 4:06:54 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Altimmune Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Harris Matthew Scott gifted 67,787 shares (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/11/25 4:05:11 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lawver Teri L

      4 - Altimmune, Inc. (0001326190) (Issuer)

      2/26/25 6:47:43 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Lawver Teri L

      3 - Altimmune, Inc. (0001326190) (Issuer)

      2/26/25 6:46:15 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Durso Jerome Benedict

      4 - Altimmune, Inc. (0001326190) (Issuer)

      2/25/25 5:46:09 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Durso Jerome Benedict

      3 - Altimmune, Inc. (0001326190) (Issuer)

      2/25/25 5:44:25 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sohn Catherine A.

      4 - Altimmune, Inc. (0001326190) (Issuer)

      2/7/25 4:05:14 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Garg Vipin K converted options into 62,270 shares, covered exercise/tax liability with 27,214 shares and was granted 4,105 shares, increasing direct ownership by 12% to 355,082 units (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      2/3/25 8:50:04 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Harris Matthew Scott converted options into 23,216 shares, covered exercise/tax liability with 7,990 shares and was granted 1,905 shares, increasing direct ownership by 26% to 81,856 units (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      2/3/25 8:48:13 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Altimmune Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Altimmune Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Altimmune

      William Blair initiated coverage of Altimmune with a rating of Mkt Perform

      2/28/25 7:17:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Altimmune with a new price target

      Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

      1/8/25 7:32:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Altimmune with a new price target

      UBS initiated coverage of Altimmune with a rating of Buy and set a new price target of $26.00

      11/12/24 7:30:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune downgraded by Guggenheim

      Guggenheim downgraded Altimmune from Buy to Neutral

      4/29/24 7:15:24 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Altimmune with a new price target

      Goldman initiated coverage of Altimmune with a rating of Neutral and set a new price target of $13.00

      1/24/24 6:55:27 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune downgraded by Goldman with a new price target

      Goldman downgraded Altimmune from Buy to Neutral and set a new price target of $6.00 from $20.00 previously

      3/22/23 7:14:39 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Altimmune with a new price target

      Goldman initiated coverage of Altimmune with a rating of Buy and set a new price target of $20.00

      12/1/22 7:22:46 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Altimmune with a new price target

      Jefferies resumed coverage of Altimmune with a rating of Buy and set a new price target of $30.00

      12/29/21 7:17:57 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on Altimmune with a new price target

      B. Riley Securities reiterated coverage of Altimmune with a rating of Buy and set a new price target of $21.00 from $41.00 previously

      6/30/21 9:04:18 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Altimmune with a new price target

      JMP Securities reiterated coverage of Altimmune with a rating of Market Outperform and set a new price target of $31.00 from $53.00 previously

      6/30/21 6:54:32 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Altimmune Inc. Leadership Updates

    Live Leadership Updates

    See more

    Altimmune Inc. Financials

    Live finance-specific insights

    See more
    • Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

      Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled

      2/25/25 7:30:00 AM ET
      $ALT
      $DXCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

      GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun

      3/27/23 4:05:00 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Appoints Raymond Jordt as Chief Business Officer

      GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option

      1/4/23 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Appoints Will Brown as Chief Financial Officer

       Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Will Brown as Chief Financial Officer and member of the company's Executive Committee, effective January 1, 2022. "We are thrilled to welcome Will, a highly accomplished biopharmaceutical executive with proven business development and financial acumen, to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "This is an exciting time for ObsEva on the heels of the

      12/13/21 1:00:00 AM ET
      $ALT
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations

      5/6/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Feb.

      2/27/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

      GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on

      2/20/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

      Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024 Webcast to be held today, November 12, 2024, at 8:30 a.m. ET GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for

      11/12/24 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

      GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay wi

      11/4/24 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

      Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "During the second

      8/8/24 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

      GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will b

      8/1/24 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

      Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. "As the obesity therapeutics space evolves, increasing attention is being placed on agents that are able to drive weight loss while addressing the qua

      5/9/24 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

      GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be availa

      5/2/24 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

      Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in anon-steatotic model of liver fibrosis Cash, cash equivalents and short-term investments of $198.0 million at December 31, 2023 Webcast to be held today, March 27, 2024, at 8:30 am ET GAITHERSBURG, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biophar

      3/27/24 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Altimmune Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

      GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress™ in Amsterdam, The Netherlands. The presentation focuses on the use of the MASH Resolution Index (MASHResInd) algorithm to predict MASH resolution on biopsy in patients treated with pemvidutide, Altimmune's 1:1 GLP-1/glucagon dual receptor agonist. Developed by Dr. Rohit Loomba, Professor of Medicine, Director of Hepatology, and Vice Chief, Division

      5/8/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations

      5/6/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

      GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index (MASHResInd; Loomba 2024), a highly sensitive non-invasive measure of MASH histologic response, in a poster session at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2025 in Amsterdam, The Netherlands. The abstract will be featured in the

      5/1/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Participate in the Citizens Life Sciences Conference

      GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows: Conference:Citizens Life Sciences ConferenceDate/Time:Wednesday, May 7, 2025, at 9:30 a.m. EDT   The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-

      4/30/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Host Virtual R&D Day on March 13, 2025

      GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering the scientific rationale for pemvidutide in each indication, clinical data generated to-date and plans for the continued development of pemvidutide, including the upcoming topline data readout from IMPACT, the Company's Phase 2b trial in MASH, which is expected in the second quarter of 2025. The e

      3/6/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Participate in the Leerink Global Healthcare Conference

      GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows: Conference:Leerink Global Healthcare Conference  Date/Time:Monday, March 10, 2025, at 3:40 p.m. EST The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide

      3/3/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Feb.

      2/27/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

      Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled

      2/25/25 7:30:00 AM ET
      $ALT
      $DXCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

      GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on

      2/20/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

      GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:  Conference:Guggenheim SMID Cap Biotech Conference    Date/Time:Wednesday, February 5, 2025, at 9:30 a.m. EST    The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is

      1/29/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care